Diagnostic surgical pathology in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines

Chest

Volumn 143, Issue 5 SUPPL, 2013, Pages

  Schwartz, Arnold M ^a   Rezaei, M Katayoon ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 20; CYTOKERATIN 7; PROTEIN P40; PROTEIN P60; PROTEIN P63; THYROID TRANSCRIPTION FACTOR 1;

ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; DATA ANALYSIS; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISTANT METASTASIS; EVIDENCE BASED MEDICINE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; MALIGNANT MESOTHELIOMA; PATHOLOGICAL ANATOMY; PATHOLOGY; PLEURA ADENOCARCINOMA; PRACTICE GUIDELINE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGIONAL METASTASIS; SURGICAL PATHOLOGY; SYSTEMATIC REVIEW; TUMOR LOCALIZATION; TUMOR VOLUME; VISCERAL METASTASIS;

EID: 84877678110     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-2356     Document Type: Article

References (76)

1. Lewis SZ, Diekemper R, Addrizzo-Harris DJ. Methodology for development of guidelines for lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5)(suppl):41S-50S.
2. Cagle PT, Allen TC, Dacic S, et al. Revolution in lung cancer: new challenges for the surgical pathologist. Arch Pathol Lab Med. 2011; 135 (1): 110-116.
3. Schwartz AM, Henson DE; American College of Chest Physicians. Diagnostic surgical pathology in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132 (suppl 3): 78S-93S.
4. Nana-Sinkam SP, Powell CA. Molecular biology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5)(suppl):e30S- e39S.
5. Travis WD. Pathology of lung cancer. Clin Chest Med. 2002; 23 (1): 65-81.
6. Franklin WA. Diagnosis of lung cancer: pathology of invasive and preinvasive neoplasia. Chest. 2000; 117 (4)(suppl 1): 80S-89S.
7. Chamberlain DW, Wenckebach GF, Alexander F, Fraser RS, Kolin A, Newman T. Pathological examination and the reporting of lung cancer specimens. Clin Lung Cancer. 2000; 1 (4): 261-268.
8. Marchevsky AM. Problems in pathologic staging of lung cancer. Arch Pathol Lab Med. 2006; 130 (3): 292-302.
9. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009; 136 (1): 260-271.
10. Tanoue LT, Detterbeck FC. New TNM classification for nonsmall-cell lung cancer. Expert Rev Anticancer Ther. 2009; 9 (4): 413-423.
11. Buccheri G, Ferrigno D. Prognostic value of stage grouping and TNM descriptors in lung cancer. Chest. 2000; 117 (5): 1247-1255.
12. Flieder DB. Commonly encountered difficulties in pathologic staging of lung cancer. Arch Pathol Lab Med. 2007; 131 (7): 1016-1026.
13. Butnor KJ, Vollmer RT, Blaszyk H, Glatz K. Interobserver agreement on what constitutes visceral pleural invasion by non-small cell lung carcinoma: an internet-based assessment of international current practices. Am J Clin Pathol. 2007; 128 (4): 638-647.
14. Leslie KO, Rosai J. Standardization of the surgical pathology report: formats, templates, and synoptic reports. Semin Diagn Pathol. 1994; 11 (4): 253-257.
15. Markel SF, Hirsch SD. Synoptic surgical pathology reporting. Hum Pathol. 1991; 22 (8): 807-810.
16. Qu Z, Ninan S, Almosa A, Chang KG, Kuruvilla S, Nguyen N. Synoptic reporting in tumor pathology: advantages of a webbased system. Am J Clin Pathol. 2007; 127 (6): 898-903.
17. Srigley JR, McGowan T, Maclean A, et al. Standardized synoptic cancer pathology reporting: a population-based approach. J Surg Oncol. 2009; 99 (8): 517-524.
18. Dworak O. Synoptic surgical pathology reporting. Hum Pathol. 1992; 23 (1): 85-86.
19. Zarbo RJ. Interinstitutional assessment of colorectal carcinoma surgical pathology report adequacy. A College of American Pathologists Q-Probes study of practice patterns from 532 laboratories and 15,940 reports. Arch Pathol Lab Med. 1992; 116 (11): 1113-1119.
20. Austin R, Thompson B, Coory M, Walpole E, Francis G, Fritschi L. Histopathology reporting of breast cancer in Queensland: the impact on the quality of reporting as a result of the introduction of recommendations. Pathology. 2009; 41 (4): 361-365.
21. Beattie GC, McAdam TK, Elliott S, Sloan JM, Irwin ST. Improvement in quality of colorectal cancer pathology reporting with a standardized proforma-a comparative study. Colorectal Dis. 2003; 5 (6): 558-562.
22. Gill AJ, Johns AL, Eckstein R, et al; New South Wales Pancreatic Cancer Network (NSWPCN). Synoptic reporting improves histopathological assessment of pancreatic resection specimens. Pathology. 2009; 41 (2): 161-167.
23. Haydu LE, Holt PE, Karim RZ, et al. Quality of histopathological reporting on melanoma and influence of use of a synoptic template. Histopathology. 2010; 56 (6): 768-774.
24. Kang HP, Devine LJ, Piccoli AL, Seethala RR, Amin W, Parwani AV. Usefulness of a synoptic data tool for reporting of head and neck neoplasms based on the College of American Pathologists cancer checklists. Am J Clin Pathol. 2009; 132 (4): 521-530.
25. Karim RZ, van den Berg KS, Colman MH, McCarthy SW, Thompson JF, Scolyer RA. The advantage of using a synoptic pathology report format for cutaneous melanoma. Histopathology. 2008; 52 (2): 130-138.
26. Idowu MO, Bekeris LG, Raab S, Ruby SG, Nakhleh RE. Adequacy of surgical pathology reporting of cancer: a College of American Pathologists Q-Probes study of 86 institutions. Arch Pathol Lab Med. 2010; 134 (7): 969-974.
27. Miller BH, Rosado-de-Christenson ML, Mason AC, Fleming MV, White CC, Krasna MJ. From the archives of the AFIP. Malignant pleural mesothelioma: radiologic-pathologic correlation. Radiographics. 1996; 16 (3): 613-644.
28. McCaughey WT, Colby TV, Battifora H, et al. Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian Mesothelioma Panel. Mod Pathol. 1991; 4 (3): 342-353.
29. Butnor KJ, Beasley MB, Kong F-M, et al. Protocol for the examination of specimens from patients with thymoma or thymic carcinoma. 2009. College of American Pathologists website. http://www.cap.org/apps/docs/committees/cancer/ cancer-protocols/2012/Mesothelioma-12protocol.pdf. Accessed March 4, 2013.
30. Tsujimura T, Torii I, Sato A, et al. Pathological and molecular biological approaches to early mesothelioma. Int J Clin Oncol. 2012; 17 (1): 40-47.
31. Rakha EA, Patil S, Abdulla K, Abdulkader M, Chaudry Z, Soomro IN. The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Diagn Cytopathol. 2010; 38 (12): 874-879.
32. Hasteh F, Lin GY, Weidner N, Michael CW. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol. 2010; 118 (2): 90-96.
33. Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol. 2000; 24 (9): 1183-1200.
34. Churg A, Cagle P, Colby TV, et al; US-Canadian Mesothelioma Reference Panel. The fake fat phenomenon in organizing pleuritis: a source of confusion with desmoplastic malignant mesotheliomas. Am J Surg Pathol. 2011; 35 (12): 1823-1829.
35. Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma. Clin Chem Lab Med. 2011; 49 (10): 1721-1726.
36. Klebe S, Nurminen M, Leigh J, Henderson DW. Diagnosis of epithelial mesothelioma using tree-based regression analysis and a minimal panel of antibodies. Pathology. 2009; 41(2): 140-148.
37. Mani H, Zander DS. Immunohistochemistry: applications to the evaluation of lung and pleural neoplasms: part 2. Chest. 2012; 142 (5): 1324-1333.
38. Kao SC, Griggs K, Lee K, et al. Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma. Pathology. 2011; 43 (4): 313-317.
39. Hanna A, Pang Y, Bedrossian CW, Dejmek A, Michael CW. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions. Diagn Cytopathol. 2010; 38 (4): 264-269.
40. Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 2008; 132(3):397-401.
41. Bedrossian CW, Bonsib S, Moran C. Differential diagnosis between mesothelioma and adenocarcinoma: a multimodal approach based on ultrastructure and immunocytochemistry. Semin Diagn Pathol. 1992; 9 (2): 124-140.
42. Dardick I, Al-Jabi M, McCaughey WT, Srigley JR, van Nostrand AW, Ritchie AC. Ultrastructure of poorly differentiated diffuse epithelial mesotheliomas. Ultrastruct Pathol. 1984; 7 (2-3): 151-160.
43. Sidhu GS. The ultrastructure of malignant epithelial neoplasms of the lung. Pathol Annu. 1982; 17 (pt 1): 235-266.
44. Travis WD. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Mod Pathol. 2012; 25 (suppl 1): S18-S30.
45. Dubinski W, Leighl NB, Tsao MS, Hwang DM. Ancillary testing in lung cancer diagnosis. Pulm Med. 2012; 2012:249082.
46. Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol. 2002; 26 (9): 1184-1197.
47. Sigel CS, Moreira AL, Travis WD, et al. Subtyping of nonsmall cell lung carcinoma: a comparison of small biopsy and cytology specimens. J Thorac Oncol. 2011; 6 (11): 1849-1856.
48. Agoff SN, Lamps LW, Philip AT, et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol. 2000; 13 (3): 238-242.
49. Johansson L. Histopathologic classification of lung cancer: Relevance of cytokeratin and TTF-1 immunophenotyping. Ann Diagn Pathol. 2004; 8 (5): 259-267.
50. Skov BG, Holm B, Erreboe A, Skov T, Mellemgaard A. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. J Thorac Oncol. 2010; 5(4):453-459.
51. Thunnissen E, Kerr KM, Herth FJ, et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer. 2012; 76(1):1-18.
52. Travis WD, Brambilla E, Noguchi M, et al; American Thoracic Society. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc. 2011; 8 (5): 381-385.
53. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011; 6 (2): 244-285.
54. Barletta JA, Yeap BY, Chirieac LR. Prognostic significance of grading in lung adenocarcinoma. Cancer. 2010; 116(3): 659-669.
55. Travis WD, Brambilla E, Van Schil P, et al. Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification. Eur Respir J. 2011; 38(2): 239-243.
56. Borczuk AC. Assessment of invasion in lung adenocarcinoma classification, including adenocarcinoma in situ and minimally invasive adenocarcinoma. Mod Pathol. 2012; 25 (suppl 1): S1-S10.
57. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995; 75 (12): 2844-2852.
58. Van Schil PE, Asamura H, Rusch VW, et al. Surgical implications of the new IASLC/ATS/ERS adenocarcinoma classification. Eur Respir J. 2012; 39 (2): 478-486.
59. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011; 24 (5): 653-664.
60. Yokose T, Suzuki K, Nagai K, Nishiwaki Y, Sasaki S, Ochiai A. Favorable and unfavorable morphological prognostic factors in peripheral adenocarcinoma of the lung 3 cm or less in diameter. Lung Cancer. 2000; 29 (3): 179-188.
61. Suzuki K, Yokose T, Yoshida J, et al. Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Ann Thorac Surg. 2000; 69 (3): 893-897.
62. Hasanovic A, Rekhtman N, Sigel CS, Moreira AL. Advances in fine needle aspiration cytology for the diagnosis of pulmonary carcinoma. Patholog Res Int. 2011; 2011:897292.
63. Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol. 2011; 24 (10): 1348-1359.
64. Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N. p40 (D Np63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol. 2012; 25(3):405-415.
65. Pelosi G, Fabbri A, Bianchi F, et al. D Np63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel twohit, sparing-material approach. J Thorac Oncol. 2012; 7(2): 281-290.
66. Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer. 2011; 117 (15): 3416-3423.
67. Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol. 2011; 6(3):451-458.
68. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010; 41 (1): 20-25.
69. Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005; 11 (10): 3766-3772.
70. Ikeda S, Fujimori M, Shibata S, et al. Combined immunohistochemistry of beta-catenin, cytokeratin 7, and cytokeratin 20 is useful in discriminating primary lung adenocarcinomas from metastatic colorectal cancer. BMC Cancer. 2006; 6 : 31.
71. Park SY, Kim BH, Kim JH, Lee S, Kang GH. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med. 2007; 131 (10): 1561-1567.
72. Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol. 2010; 23 (5): 654-661.
73. Lotan TL, Ye H, Melamed J, Wu XR, Shih IeM, Epstein JI. Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma. Am J Surg Pathol. 2009; 33 (7): 1037-1041.
74. Ciampa A, Fanger G, Khan A, Rock KL, Xu B. Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas. Cancer. 2004; 102 (6): 368-372.
75. Saad RS, Cho P, Silverman JF, Liu Y. Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma. Am J Clin Pathol. 2004; 122 (3): 421-427.
76. Saad RS, Essig DL, Silverman JF, Liu Y. Diagnostic utility of CDX-2 expression in separating metastatic gastrointestinal adenocarcinoma from other metastatic adenocarcinoma in fine-needle aspiration cytology using cell blocks. Cancer. 2004; 102 (3): 168-173.